Polymyxin B Sulfate

CHEMBL5314355 Phase 4 Approved Protein

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

— g/mol

LogP

—

Phase

4

Polymyxin B sulfate is the sulfate salt form of polymyxin B, a last-resort cyclic lipopeptide antibiotic targeting the outer membrane of Gram-negative bacteria including multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. See polymyxin b for complete pharmacological details.

Therapeutic Areas

Age-Related Macular Degeneration Alzheimer's Disease Anesthesiology Asthma Atopic Dermatitis Atrial Fibrillation Benign Prostatic Hyperplasia Bipolar Disorder Bladder Cancer Breast Cancer Cardiovascular Disease Chronic Kidney Disease Chronic Obstructive Pulmonary Disease Chronic Pain Colorectal Cancer Deep Vein Thrombosis / Pulmonary Embolism Dermatology Endocrinology Endometriosis Epilepsy Gastroenterology Gastroesophageal Reflux Disease Generalized Anxiety Disorder Glaucoma Gout Heart Failure Hematology Hepatitis C Hepatology HIV/AIDS Hyperlipidemia Hypertension Immunology Infectious Disease Inflammatory Bowel Disease Insomnia Leukemia Lymphoma Major Depressive Disorder Malaria Melanoma Migraine Multiple Sclerosis Nephrology Neurology Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Obstetrics & Gynecology Oncology Ophthalmology Osteoporosis Ovarian Cancer Pain Management Pancreatic Cancer Parkinson's Disease Prostate Cancer Psoriasis Psychiatry Respiratory Disease Rheumatoid Arthritis Rheumatology Schizophrenia Stroke Systemic Lupus Erythematosus Thyroid Cancer Transplant Medicine Tuberculosis Type 2 Diabetes Urology

Pharmacokinetics (PK)

Pharmacodynamics (PD)

HBD / HBA

- / -

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

Polymyxin B sulfate is the sulfate salt form of polymyxin B, a last-resort cyclic lipopeptide antibiotic targeting the outer membrane of Gram-negative bacteria including multidrug-resistant Pseudomonas aeruginosa and Acinetobacter baumannii. See polymyxin b for complete pharmacological details.

Yes, Polymyxin B Sulfate is an approved drug. It has reached clinical phase 4. It is classified as a Protein.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL5314355. Open-access bioactivity database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-02-27.

PillFYI

Looking for patient-friendly information?

Polymyxin B Sulfate on PillFYI

Quick Data

Synonyms: 296

External Links

ChEMBL CHEMBL5314355

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.